Taiho Pharmaceutical Adds Fine Granule Formulation To Cancer Drug TS-1
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based Taiho Pharmaceutical June 11 launched a new fine-granule formulation for its cancer drug TS-1 (fluorouracil, 5-FU). Compared to current capsules, the new type allows easier swallowing for larynx cancer patients who suffer from narrowed throat. (Click here for more - Japanese language